MENU
Articles by #hashtag

abbVie

4 hits

Further FDA Approval for Gedeon Richter Drug

D&T
Dec 19, 2022

The Hungarian pharma company Gedon Richter’s partner AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR® (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for […]

New Cooperation Between AbbVie and Gedeon Richter

D&T
Mar 12, 2022

AbbVie and Gedeon Richter Plc. have announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter […]

Application to FDA for Further Use of Cariprazine

D&T
Feb 22, 2022

AbbVie, the partner company of the Hungarian pharmaceutical firm Gedeon Richter Plc., has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy. The submission is supported by results from […]

Richter Expands Cooperation to Japan and Taiwan

D&T
Jun 2, 2021

Gedeon Richter Plc. has announced that it extended its existing licensing agreement with AbbVie, originally dated 2004, for the development and commercialization of its own-developed molecule, cariprazine. The initial agreement covered the territories of the USA and Canada and was extended in 2019 to include certain countries in Latin America. The present agreement further expands […]

© Copyright 2024 Duax Kft. –  All rights reserved.
sun